Collaboration
Translational
Real World Data
Knowledge
Value
PBPK
EHR
QSP
MBDD
Study Design
Systems Pharmacology
Efficiency
Target Validation
Integration
Data Science
Electronic Health Records
Pharmacometrics
Safety
Data Mining
Pts
Outcomes
Reverse Translation Crowd Sourcing Results

Sree Kasichayanula, PhD
Karthik Venkatakrishnan, PhD

Reverse Translation Symposium, ASCPT Annual Meeting
March 18th, 2017
Q1) Please identify your primary sector of affiliation

- Academia: (11.8%)
- Industry: (79.4%)
- Consulting: (7.4%)
- Government: (1.5%)
- Other (please specify): None
Q2) What function(s) do you represent?

- Clinical Pharmacologist (80.9%)
- Pharmacometric Scientist (39.7%)
- Quantitative Systems... (26.5%)
- Data Scientist (2.9%)
- Translational Research... (19.1%)
- Other (please specify) (7.4%)

Other: Precision-medicine Methodologist, Statistician, Translational medicine, Physician

N= 68
Q3) Is there an expectation or mandate within your organization that you will leverage prior internal/external clinical data to inform early clinical development?

- Yes, but not consistently: (29.4%)
- Yes, very consistently: (51.5%)
- No: (7.4%)
- Not sure: (4.4%)
- Not applicable: (7.4%)

N= 68
Q4) Does your organization approach “knowledge capture” through models (e.g. platform models, disease models, systems models) that can be re-cycled for many projects?

- Yes, consistently (26.9%)
- Yes, but not consistently (55.2%)
- No (13.4%)
- Not applicable; ... (4.5%)

N= 67
Q5) Does your organization regularly review emerging internal/external data from clinical trials in cross functional setting (pre-clinical, pharmacometrics/Modeling and Simulations, biomarkers and physician-scientist) to inform clinical development strategies?

- Yes, but not regularly: 35.8%
- Yes, very regularly: 40.3%
- No: 11.9%
- Not sure: 3.0%
- Not applicable; ...: 9.0%

N = 68
Q6) Do you apply modeling and simulation paradigms that leverage data from marketed/late stage molecules to inform development of molecules that share related MoA?

- Yes, but not regularly: 42.7%
- Yes, very regularly: 39.7%
- No: 8.8%
- Not sure: 1.5%
- Not applicable; ...: 7.4%

N = 68
Q7) Do you apply modeling and simulation paradigms that leverage data from marketed/late stage molecules to inform development of molecules that are being developed for the same disease?

- Yes, but not regularly: (41.2%)
- Yes, very regularly: (39.7%)
- No: (8.8%)
- Not sure: (1.5%)
- Not applicable; ...: (8.8%)

N= 68
Q8) Do you encourage your discovery teams to use pertinent clinical data with an eye toward optimizing discovery of new molecular entities?

- Yes, consistently: 24.6%
- Yes, but not consistently: 46.2%
- No: 16.9%
- Not applicable; ...: 12.3%

N = 65
Q9) Do you use real world data e.g., electronic medical records, biobanks, registries, observational data, adverse event databases to inform development of target product profile and/ or design of clinical studies?

- Yes, very consistently: (11.8%)
- Yes, but not consistently: (44.1%)
- No: (23.5%)
- Not sure: (11.8%)
- Not applicable; ...: (8.8%)
Acknowledgments

• Lisa Williamson (ASCPT)
• Amin Rostami-Hodjegan
• Anne Heatherington
• John Gibbs
• Nicholas Tatonetti
• Survey participants
  – Please continue participating in the survey